HSCT in Patients with Hemoglobinopathies
摘要
HemoglobinopathiesHemoglobinopathies, are a group of monogenic inherited disorders that affect the structure or production of the globin chains. Improvements in red blood cell transfusion management and its potential complications have influenced the prognosis of patients. However cardiovascular diseaseCardiovascular disease represents the leading etiology of morbidity and mortality in thalassemiaThalassemia, as well as a main determinant of prognosis inSickle cell disease SCD. In spite of noteworthy advances in medical care for severe hemoglobinopathies, allogeneic HSCTAllogeneic HSCT remains the only definitive treatment available. This chapter aims to discuss the cardiovascular considerations of patients with hemoglobinopathies in the setting of hematopoietic stem cell transplantationHematopoietic Stem Cell Transplantation (HSCT).